Clinical Trial Detail

NCT ID NCT03377023
Title Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

lung non-small cell carcinoma

Therapies

Ipilimumab + Nivolumab

Ipilimumab + Nintedanib + Nivolumab

Age Groups: adult senior

No variant requirements are available.